MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvalsAug 5Quarterly updatefurosemide injection 80 mg/ 10 mlinsulin human
MannKind registers Phase 2 trial of inhaled nintedanib for pulmonary fibrosisJul 1Trial updateMannkind Corporationnintedanib
Sign inSign in